PH19942A - Microencapsulation of water soluble polypeptides - Google Patents

Microencapsulation of water soluble polypeptides

Info

Publication number
PH19942A
PH19942A PH26504A PH26504A PH19942A PH 19942 A PH19942 A PH 19942A PH 26504 A PH26504 A PH 26504A PH 26504 A PH26504 A PH 26504A PH 19942 A PH19942 A PH 19942A
Authority
PH
Philippines
Prior art keywords
microencapsulation
water soluble
soluble polypeptides
water
biocompatable
Prior art date
Application number
PH26504A
Other languages
English (en)
Inventor
John Scott Kent
Linda M Sanders
Danny H Lewis
Thomas R Tice
Original Assignee
Sintex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH19942(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sintex Inc filed Critical Sintex Inc
Publication of PH19942A publication Critical patent/PH19942A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH26504A 1980-11-18 1980-11-16 Microencapsulation of water soluble polypeptides PH19942A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20786480A 1980-11-18 1980-11-18

Publications (1)

Publication Number Publication Date
PH19942A true PH19942A (en) 1986-08-14

Family

ID=22772297

Family Applications (1)

Application Number Title Priority Date Filing Date
PH26504A PH19942A (en) 1980-11-18 1980-11-16 Microencapsulation of water soluble polypeptides

Country Status (15)

Country Link
EP (1) EP0052510B2 (fr)
JP (1) JPS57118512A (fr)
AT (1) ATE21624T1 (fr)
AU (1) AU556754B2 (fr)
CA (1) CA1176565A (fr)
DE (2) DE3175230D1 (fr)
HK (1) HK20489A (fr)
IE (1) IE52003B1 (fr)
IL (1) IL64298A (fr)
MY (1) MY8700835A (fr)
NL (1) NL930001I2 (fr)
NZ (1) NZ198982A (fr)
PH (1) PH19942A (fr)
SG (1) SG94487G (fr)
ZA (1) ZA817973B (fr)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
AU567155B2 (en) * 1983-04-15 1987-11-12 Damon Biotech Inc. Capsules for releasing core material at constant rate
US4652443A (en) * 1983-06-07 1987-03-24 Japan Atomic Energy Research Institute Slow-release composite and process for producing the same
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
DE3428372A1 (de) * 1984-08-01 1986-02-13 Hoechst Ag, 6230 Frankfurt Mikrokapseln von regulatorischen peptiden mit kontrollierter freisetzung, verfahren zu ihrer herstellung und injektionszubereitungen
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US5059422A (en) * 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US5169633A (en) * 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
CH669506A5 (en) * 1986-01-13 1989-03-31 Hugo Degen Oscillating and reclining furniture
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
JP2526589B2 (ja) * 1986-08-08 1996-08-21 武田薬品工業株式会社 ペプチド含有マイクロカプセルおよびその製造法
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
ES2102347T3 (es) 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5212154A (en) * 1987-08-14 1993-05-18 Akzo N.V. Preparation for treating complications in diabetes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
AU2810189A (en) * 1987-10-30 1989-05-23 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
ZA905327B (en) * 1989-07-07 1992-03-25 Sandoz Ltd Sustained release formulations of water soluble peptides
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CH679207A5 (fr) * 1989-07-28 1992-01-15 Debiopharm Sa
US5084443A (en) * 1989-12-04 1992-01-28 Biomeasure, Inc. Promoting expression of acetylcholine receptors with lhrh antagonist
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6353030B1 (en) 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
DE4041563A1 (de) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
AU8303691A (en) 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
DE69233022T2 (de) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US6005067A (en) 1992-01-24 1999-12-21 Cargill Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5247058A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5258488A (en) * 1992-01-24 1993-11-02 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5247059A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for the manufacture of a purified lactide from esters of lactic acid
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6326458B1 (en) 1992-01-24 2001-12-04 Cargill, Inc. Continuous process for the manufacture of lactide and lactide polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
DE4223169C1 (de) 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
EP0595030A3 (fr) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Composition de microsphères à plusieurs noyaux à libération retardée et son procédé de préparation.
JP3258326B2 (ja) * 1992-10-02 2002-02-18 カーギル， インコーポレイテッド 溶融安定性ラクチドポリマーをコーティングした紙とその製造方法
CA2124842C (fr) * 1992-10-02 2003-07-15 Patrick R. Gruber Tissu polymerique a base de lactide stable et procede pour sa fabrication
US6005068A (en) * 1992-10-02 1999-12-21 Cargill Incorporated Melt-stable amorphous lactide polymer film and process for manufacture thereof
US5338822A (en) * 1992-10-02 1994-08-16 Cargill, Incorporated Melt-stable lactide polymer composition and process for manufacture thereof
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
CA2170641C (fr) 1993-08-30 2011-11-15 James R. Smith Inhibiteurs de la synthese de l'adn, derives de cellules senescentes
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
FR2713933B1 (fr) * 1993-12-16 1996-02-02 Rhone Merieux Méthode de superovulation des femelles bovines, méthode de mise en anoestrus et kit approprié.
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
CA2192773C (fr) 1995-12-15 2008-09-23 Hiroaki Okada Obtention d'une preparation a liberation prolongee pour injection
WO1997026869A1 (fr) * 1996-01-24 1997-07-31 United States Government Represented By The Secretary Of The Army Nouvelles microspheres de poly-(lactide/glucolide) a liberation prolongee 'sans eclatement'
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ES2180032T3 (es) 1996-10-15 2003-02-01 Janssen Pharmaceutica Nv Procedimiento para preparar un compuesto intermedio util en la sintesis de cisaprida.
EP0839525B1 (fr) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Préparation à libération retardée
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
EP2050762A3 (fr) 1998-03-10 2009-07-08 Genentech, Inc. Nouvelles polypeptides et acides nucléiques les codant
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
AU4390200A (en) * 1999-02-19 2000-09-04 Bioserv Ag Biodegradable composite material for the production of microcapsules
EP2286847A1 (fr) 1999-10-15 2011-02-23 Genetics Institute, LLC Formulations à base d'acide hyaluronique aux fins de l'administration de proteines osteogenes
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
TW200800298A (en) 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
DK1310517T4 (da) 2000-08-07 2011-01-17 Wako Pure Chem Ind Ltd Mælkesyrepolymer og fremgangsmåde til fremstilling af denne
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
WO2003000156A1 (fr) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
TWI332407B (en) 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
EP1275378B1 (fr) 2001-07-10 2009-04-15 Canon Kabushiki Kaisha Particules à base d' un polyhydroxyalcanoate et leur procédé de préparation
US20040191215A1 (en) * 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
ES2282904T3 (es) 2003-09-12 2007-10-16 Wyeth Barras solidas de fosfato calcico inyectables para el suministro de proteinas osteogenicas.
WO2005110425A1 (fr) 2004-04-15 2005-11-24 Alkermes, Inc. Dispositif à libération contrôlée à base de polymère
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
EP1751115A4 (fr) 2004-05-23 2010-10-20 Gerard M Housey Modulateurs de theramuteine
US9345911B2 (en) * 2004-08-04 2016-05-24 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
PL1824460T3 (pl) 2004-11-10 2015-09-30 Tolmar Therapeutics Inc Stabilizowany polimerowy układ dostarczania
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
EP2163562B1 (fr) 2005-06-21 2013-09-18 XOMA Technology Ltd. Anticorps se liant à IL-1 beta et fragments de ceux-ci
JP5072057B2 (ja) * 2005-08-22 2012-11-14 東ソー株式会社 微小流路構造体を用いたマイクロカプセルの製造方法
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
TWI481424B (zh) 2006-12-18 2015-04-21 Takeda Pharmaceutical 緩釋性組成物及其製法
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
CA3056116A1 (fr) 2007-06-22 2008-12-31 Randolph Watnick Procedes et utilisations de prosaposine
HRP20141194T1 (hr) 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
EP2405903B1 (fr) 2009-03-09 2024-04-10 Basf As Compositions comprenant un mélange oléagineux à base d'acides gras et d'un acide gras libre, et procédés et utilisations associés
WO2010144797A2 (fr) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations
EP3735944A1 (fr) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Établissement rapide et/ou arrêt rapide d'une administration constante substantielle de médicament
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
EP2513137B1 (fr) 2009-12-17 2018-02-28 Children's Medical Center Corporation Peptides dérivés de saposine a et utilisations de ceux-ci
EP2517697B1 (fr) 2009-12-23 2015-01-07 Sigma-Tau Industrie Farmaceutiche Riunite SpA Composition de combinaison utiles pour traiter des maladies cardiovasculaires
EP2550289A4 (fr) 2010-03-12 2013-11-27 Childrens Medical Center Nouveaux immunogènes et procédés pour la découverte et le dépistage de ceux-ci
ES2383271B1 (es) 2010-03-24 2013-08-01 Lipotec S.A. Procedimiento de tratamiento de fibras y/o materiales textiles
US9993019B2 (en) 2010-03-26 2018-06-12 Philip Morris Usa Inc. Method for making particle of a hydrophobic additive and a polysaccharide coating and tobacco products containing particle of a hydrophobic additive and a polysaccharide coating
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
WO2012092539A2 (fr) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps contre dll4 et leurs utilisations
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012253359B2 (en) 2011-05-11 2017-06-08 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
ES2664224T3 (es) 2011-08-19 2018-04-18 Children's Medical Center Corporation Proteína de unión a VEGF para el bloqueo de la angiogénesis
DE102011114864A1 (de) * 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
WO2013072767A1 (fr) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions et préconcentrés comprenant au moins un salicylate et un mélange huileux d'acide gras oméga-3
CN102511790B (zh) * 2011-12-05 2013-07-24 山东好当家海洋发展股份有限公司 一种水产蛋白肽微胶囊的制备方法
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
EP3050900A1 (fr) 2011-12-19 2016-08-03 Xoma (Us) Llc Procédés pour le traitement de l'acnée
AU2012358269B2 (en) 2011-12-22 2017-11-02 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
WO2013106489A1 (fr) 2012-01-09 2013-07-18 The Scripps Research Institute Anticorps humanisés à cdr3 ultralongues
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
US9585896B2 (en) 2012-04-04 2017-03-07 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
US20150079164A1 (en) 2012-04-04 2015-03-19 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
CA2900008C (fr) 2013-02-07 2025-10-07 Children's Medical Center Corporation Antigenes de proteine qui conferent une protection contre une colonisation et/ou une maladie pneumococcique
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
EP3022224A2 (fr) 2013-07-18 2016-05-25 Fabrus, Inc. Anticorps à régions de détermination de complémentarité ultralongues
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3057991B8 (fr) 2013-10-15 2019-09-04 The Scripps Research Institute Commutateurs de lymphocytes t des récepteurs d'antigène chimériques et leur utilisation
EP3057994B1 (fr) 2013-10-15 2020-09-23 The Scripps Research Institute Commutateurs de cellules t à récepteur d'antigène chimère peptidique et leurs utilisations
CA2933701C (fr) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Agents therapeutiques modifies, conjugues lipide-peptide agrafes, et compositions les comprenant
EP2977758A1 (fr) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Procédés et kits pour surveiller la néphropathie membraneuse
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016154621A1 (fr) 2015-03-26 2016-09-29 The California Institute For Biomedical Research Récepteurs chimériques non-scfv commutables, commutateurs, et leurs utilisations
EP3283113A4 (fr) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Commutateurs de lymphocytes t à récepteurs d'antigènes chimères à base de pne optimisés et leurs utilisations
WO2016205488A1 (fr) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Agents thérapeutiques modifiés et compositions associées
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
WO2018075807A1 (fr) 2016-10-19 2018-04-26 California Institute For Biomedical Research Commutateurs de cellules effectrices à récepteurs chimériques d'antigène à fractions de ciblage humanisées et/ou à domaines d'interaction de récepteurs chimériques d'antigène optimisés et leurs utilisations
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
EP3687503A1 (fr) 2017-09-26 2020-08-05 Nanomi B.V. Procédé de préparation de microparticules par une technique de double émulsion
CA3103265A1 (fr) 2018-06-12 2019-12-19 Angiex, Inc. Conjugues anticorps-oligonucleotide
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
CN110585170A (zh) * 2019-09-17 2019-12-20 南京赛弗斯医药科技有限公司 一种采用3d打印制备的醋酸特利加压素注射用缓释微球及其制备方法
US20220380487A1 (en) 2019-10-24 2022-12-01 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
WO2021134623A1 (fr) 2019-12-31 2021-07-08 广州帝奇医药技术有限公司 Composition pharmaceutique d'amine tertiaire et son procédé industriel de préparation par lots
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
CN117794946A (zh) 2021-06-09 2024-03-29 斯克利普斯研究所 长效双重gip/glp-1肽缀合物及使用方法
EP4514389A1 (fr) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Méthodes et compositions pour le traitement de maladies et de troubles à éosinophiles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5324423B2 (fr) * 1972-04-29 1978-07-20
JPS5017525A (fr) * 1973-06-14 1975-02-24
JPS5035158A (fr) * 1973-07-24 1975-04-03
JPS5749532B2 (fr) * 1974-03-19 1982-10-22
JPS5314072B2 (fr) * 1973-09-29 1978-05-15
JPS5726506B2 (fr) * 1974-03-08 1982-06-04
NZ181036A (en) * 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
CH649217A5 (de) * 1977-08-25 1985-05-15 Sandoz Ag Bromocriptin enthaltende mikrokapseln.
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone

Also Published As

Publication number Publication date
IE52003B1 (en) 1987-05-13
JPS57118512A (en) 1982-07-23
CA1176565A (fr) 1984-10-23
HK20489A (en) 1989-03-17
IL64298A0 (en) 1982-02-28
NL930001I1 (nl) 1993-02-16
SG94487G (en) 1988-05-06
DE3175230D1 (en) 1986-10-02
ZA817973B (en) 1983-07-27
ATE21624T1 (de) 1986-09-15
IL64298A (en) 1985-07-31
EP0052510B1 (fr) 1986-08-27
MY8700835A (en) 1987-12-31
EP0052510A2 (fr) 1982-05-26
DE52510T1 (de) 1986-03-20
EP0052510A3 (en) 1982-09-08
AU556754B2 (en) 1986-11-20
NL930001I2 (nl) 1997-05-01
AU7756081A (en) 1982-05-27
EP0052510B2 (fr) 1994-10-19
IE812695L (en) 1982-05-18
JPH0440329B2 (fr) 1992-07-02
NZ198982A (en) 1985-05-31

Similar Documents

Publication Publication Date Title
DE3175230D1 (en) Microencapsulation of water soluble polypeptides
EP0266119A3 (en) Method and formulation for orally administering bioactive agents to and through the peyer's patch
ZA9811377B (en) Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
IL136054A0 (en) Poly(vinylamine) -based superabsorbent gels and method of manufacturing the same
HK60292A (en) Detergent compositions
HK33294A (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein
CA2074322A1 (fr) Composition pour la liberation prolongee et lente d'un produit medicamenteux et methode de preparation
CA2215495A1 (fr) Compositions de gomme a macher ecologiques contenant des polymeres elastiques protidiques
HK97695A (en) Sustained release formulations of water soluble peptides
ZA888315B (en) Method of solidification and encapsulation using core-shell polymer particles
EP0357401A3 (en) Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
ATE107469T1 (de) Pestizide wirkstoffkonzentrate und ihre herstellung.
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
PL310072A1 (en) Small-diameter microcapsules, method of making them and their applications
MXPA02002409A (es) Microcapsulas de liberacion variable.
ES2073522T3 (es) Copolimeros de urea de poliuretano procesables en fusion y metodo para su preparacion.
EP0381529A3 (fr) Rafraíchisseur de l'air
BR9104426A (pt) Metodo para impedir a alogmeracao de po,agente anti-aglomeracao e po
DE69825769D1 (de) Eingekapselte wasserdispergierbare perfluoroetherpolymere
Kryzhavskii et al. Properties of Network Polymers Deformed in the High-Elastic State
CA2189254A1 (fr) Liberation modulee de polymeres biocompatibles
NZ237900A (en) Microparticles suitable as ultrasonic contrast agent comprising biodegradable polymers; preparation thereof
IL74692A0 (en) Pharmaceutical compositions comprising 4,9-dihydro-4(1-methyl-4-piperidinylidene)-10h-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one and a biodegradable polymer